Lineage switch of KMT2A-rearranged adult B-lineage acute lymphoblastic leukemia following bispecific T-cell engager and monoclonal antibody therapy
We report the disease course of a patient with B-ALL with t(4;11)(q21;q23) to demonstrate that close monitoring of cell morphology and immunophenotyping is necessary to capture the lineage switch at an early stage. Cell morphology, immunophenotyping, and cytogenetics were used to evaluate the patient ’s disease status. A 36-year-old woman was diagnosed with B-ALL with t(4;11)(q21;q23), which encodes theKMT2A::AFF1 fusion. After the initial induction chemotherapy, her disease remained refractory, and the patient received salvage immunotherapy with blinatumomab and inotuzumab ozogamicin. However, the ALL did not respond. R...
Source: Journal of Hematopathology - March 22, 2023 Category: Pathology Source Type: research
Epithelioid inflammatory myofibroblastic sarcoma: a pitfall in the differential diagnosis of ALK-positive anaplastic large cell lymphoma
(Source: Journal of Hematopathology)
Source: Journal of Hematopathology - March 14, 2023 Category: Pathology Source Type: research
Effect of changes in lymphocyte subsets at diagnosis in acute myeloid leukemia on prognosis: association with complete remission rates and relapse free survivals
AbstractWe prospectively investigated whether the characteristics of lymphocyte subsets at diagnosis in acute myeloid leukemia (AML) patients are different from healthy controls and affect treatment outcomes. A total of 91 AML patients classified into 3 genetic risk subgroups (favorable/intermediate/poor) according to 2022 NCCN guidelines were enrolled. We measured lymphocyte subsets by flow cytometry with peripheral blood samples at diagnosis and compared results with healthy controls. Influences of lymphocyte subsets on complete remission (CR) rates and survivals were also evaluated. AML patients had significantly lower ...
Source: Journal of Hematopathology - March 7, 2023 Category: Pathology Source Type: research
The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory
This study aims to evaluate the impact of the 2022 ICC and WHO 5th edition classifications on the diagnosis of cytopenias and MDS. Cases from 2021 performed for primary diagnosis of cytopenia(s)/MDS and their clinical, laboratory, and pathologic findings were reviewed and classified according to the new classification systems. The rate of major changes to the diagnosis was determined and potential pitfalls in the diagnostic approach, laboratory workflow, and clinical communication challenges were investigated. A total of 49 cases were recruited. Major changes to the diagnostic entities were made in 18/49 (37%) cases accord...
Source: Journal of Hematopathology - March 7, 2023 Category: Pathology Source Type: research
Mixed-phenotype acute leukemia, T/megakaryoblastic: does it really exist?
We report the clinical presentation, diagnostic profile, and disease course of MPAL cases with a biphenotypic pattern consistent with T/megakaryoblastic lineage which is not yet defined in WHO classification. These cases were phenotyped using 8-color flow cytometry (BD FACS CANTO-II) using an extensive panel of markers. Interphase fluorescence in situ hybridization (FISH) was done using dual color dual fusion probes forBCR::ABL1,RUNX1::RUNX1T1, andETV6::RUNX1, whileMLL andCBFB gene rearrangement was tested by break-apart probes. Karyotyping was performed using the conventional GTG-banding technique. Both FISH and karyotypi...
Source: Journal of Hematopathology - March 1, 2023 Category: Pathology Source Type: research
Trouble afoot: Mycosis fungoides bullosa at an unusual site
(Source: Journal of Hematopathology)
Source: Journal of Hematopathology - March 1, 2023 Category: Pathology Source Type: research
TRBC1 enables identification of an otherwise immunophenotypically silent case of angioimmunoblastic T-cell lymphoma
(Source: Journal of Hematopathology)
Source: Journal of Hematopathology - February 22, 2023 Category: Pathology Source Type: research
Reviewer Thank You
(Source: Journal of Hematopathology)
Source: Journal of Hematopathology - February 10, 2023 Category: Pathology Source Type: research
We would like to thank all those listed below for taking the time to review for the Journal of Hematopathology in 2022; your generosity is much appreciated, and we hope your association with the journal continues in the future
(Source: Journal of Hematopathology)
Source: Journal of Hematopathology - February 10, 2023 Category: Pathology Source Type: research
PD-L1 immunohistochemistry assay optimization to provide more comprehensive pathological information in classic Hodgkin lymphoma
In this study, we sought to optimize the PD-L1 immunohistochemistry (IHC) assay in CHL. All tests were performed on a tumour tissue microarray established from 54 CHL cases. Three IHC antibodies (405.9A11, SP142, 22C3) for detecting PD-L1 expression were compared semi quantitatively with the RNAscope assay (No. 310035, ACD), and the difference in the expression in background immune cells (ICs) between assays and the associations of expression levels with densities of TILs/TAMs were also analysed. 405.9A11 demonstrated best specificity in HRS cells and best sensitivity in ICs. Positive expression of PD-L1 was more frequent ...
Source: Journal of Hematopathology - February 1, 2023 Category: Pathology Source Type: research
Comparison of two immunohistochemical staining protocols for ALK demonstrates non-inferiority of a 5A4 clone-based protocol versus an ALK01 clone-based protocol for the diagnosis of ALK + anaplastic large cell lymphoma
AbstractDetection of ALK rearrangement and/or expression of the ALK protein is an essential component in the evaluation of many neoplasms. Variability has been reported in the ability of different antibody clones to detect ALK expression. The ALK01 clone is commonly used to detect ALK expression in ALK-positive anaplastic large cell lymphoma (ALK + ALCL). However, this clone has been shown to lack sensitivity when used for solid tumors. The aim of this study was to determine if our high-sensitivity 5A4-based immunohistochemistry protocol is non-inferior to our ALK01-based protocol for the detection of ALK expression i...
Source: Journal of Hematopathology - January 31, 2023 Category: Pathology Source Type: research
Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25 —a case report of rare entity
AbstractSystemic mastocytosis (SM) is a rare hematological neoplasm caused by the excessive proliferation of pathological mast cells that accumulate in the bone marrow (BM) and other extracutaneous organs leading to multi-organ damage and failure. Mast cell leukemia (MCL) is a rare form of systemic mastocytosis, accounting for < 1% of all cases of mastocytosis. MCL usually behaves aggressively with poor responses to current treatment options. Here, we report a diagnostic challenge with the leukemic subtype of MCL with a primary suspicion of pancreatic cancer. A cytomorphological, immunophenotypic, and histopatholo...
Source: Journal of Hematopathology - January 20, 2023 Category: Pathology Source Type: research
A case of clinically aggressive EBV-negative ENKTL in a non-Asian female patient
AbstractBackgroundThe patient was a 65-year-old White woman who presented to dermatology with a painless, rapidly growing exophytic nodule on her left upper cheek.Aims/purposeIn this case report, we aim to demonstrate the difficulty of diagnosing Epstein-Barr virus-negative extranodal NK cell lymphomas given the broad differential of NK cell lymphomas and the rarity of EBV-negative extranodal NK cell lymphoma.MethodsImmunohistochemical studies confirmed the diagnosis of cutaneous, extranodal NK cell lymphoma. Interestingly, Epstein-Barr virus in situ hybridization was negative, which is unusual for most NK cell lymphomas.R...
Source: Journal of Hematopathology - January 19, 2023 Category: Pathology Source Type: research
Flow cytometric measurable residual disease in adult acute myeloid leukemia: a preliminary report from Eastern India
AbstractPresence of measurable residual disease (MRD) in acute myeloid leukemia (AML) is considered to be an independent predictor of relapse and poorer survival outcomes. MRD can be measured by flow cytometric, quantitative PCR, and NGS-based assays at varying sensitivities. There is scant Indian data on different aspects of MFC-MRD in AML including analysis strategies as well as molecular spectrum, clinical correlation, etc. This retrospective observational study included all newly diagnosed patients of acute myeloid leukemia in whom complete baseline diagnostic workup was available including flow cytometry and cytogenet...
Source: Journal of Hematopathology - January 10, 2023 Category: Pathology Source Type: research
Myeloid and lymphoid neoplasm with novel complex translocation: unusual case report with T-lymphoblastic lymphoma, myeloid hyperplasia, eosinophilia, basophilia, and t(1;8;10)( (p31;q24;q11.2)
AbstractMyeloid and lymphoid neoplasms with eosinophilia (M/Ls-Eo) encompass heterogeneous but aggressive hematopoietic disorders triggered by fusion genes or mutations that typically lead to constitutive overexpression of tyrosine kinase. The occurrence of T-lymphoblastic lymphoma in the setting of M/Ls-Eo has been reported rarely in the literature. Herein, we present an unusual case of a 28-year-old male patient who presented with massive lymphadenopathy and T-lymphoblastic lymphoma in the lymph node occurring concurrently with myeloid hyperplasia, eosinophilia and basophilia in peripheral blood and bone marrow biopsy. T...
Source: Journal of Hematopathology - December 29, 2022 Category: Pathology Source Type: research
